Tirzepatide as Compared with Semaglutide for the Treatment of Obesity

2025297 citationsJournal Article

Authors

Louis J. Aronne · Weill Cornell Medicine

Deborah B. Horn · The University of Texas Health Science Center at Houston

Carel W. le Roux · Conway School of Landscape Design

Wayne Ho · University of California, Los Angeles

Beverly L. Falcón · Eli Lilly (United States)

Elisa Gomez Valderas · Eli Lilly (United States)

Swapan Kumar Das

Abstract

Among participants with obesity but without diabetes, treatment with tirzepatide was superior to treatment with semaglutide with respect to reduction in body weight and waist circumference at week 72. (Funded by Eli Lilly; SURMOUNT-5 ClinicalTrials.gov number, NCT05822830.).

Topics & Keywords

Pharmacology and Obesity Treatment Diabetes Treatment and Management Metabolism, Diabetes, and Cancer

UN Sustainable Development Goals

Zero hunger

Publication Details

Published in: New England Journal of Medicine

Volume 393, Issue 1, pp. 26-36

DOI: 10.1056/nejmoa2416394

Field-Weighted Citation Impact: 402.93